Animal models of alzheimer's disease: An understanding of pathology and therapeutic avenues

International Journal of Neuroscience

Volumn 120, Issue 8, 2010, Pages 531-537

  Obulesu, M ^a   Rao, Dowlathabad Muralidhara ^b  

^a JSS MEDICAL COLLEGE   (India)

^b Srikrishna Devaraya University   (India)

Author keywords

Alzheimer's disease; Animal model; Therapeutic strategies

Indexed keywords

1 3 N BUTYLPHTHALIDE; 3 BUTYLPHTHALIDE; ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; ANGIOTENSIN II [3-8]; BAFILOMYCIN; CURCUMIN; DNA VACCINE; DONEPEZIL; GANSTIGMINE; GLOXAZONE; GLYCOGEN SYNTHASE KINASE 3; IBUPROFEN; NEUTRALIZING ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; RESVERATROL; SOMATOMEDIN C; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL MODEL; BEHAVIOR DISORDER; BLOOD BRAIN BARRIER; BRAIN INJURY; COGNITION; COGNITIVE DEFECT; DIET; DISEASE COURSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; ENZYME INHIBITION; GLIOSIS; HYPOXIA; ISCHEMIA; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RABBIT; REVIEW; SPINAL CORD INJURY; STEM CELL; TRANSGENIC MOUSE; TREATMENT PLANNING; ZEBRA FISH; ANIMAL; DISEASE MODEL; HUMAN; PATHOLOGY;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; HUMANS;

EID: 77954478325     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207451003760080     Document Type: Review

References (72)

1. Abrahamson, E. E., Ikonomovic, M. D., Ciallella, J. R.,Hope, C. E., Paljug, W. R., Isanski, B. A., et al. (2006). Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: Implications for clinical outcome. Experimental Neurology, 197(2), 437-450.
2. Bai, Q., Garver, J. A., Hukriede, N. A., & Burton, E. A. (2007). Generation of a transgenic zebrafish model of tauopathy using a novel promoter element derived from the zebrafish eno2 gene. Nucleic Acids Research, 35(19), 6501-6516.
3. Bard, F., Cannon, C., Barbour, R., Burke, R. L., Games, D., Grajeda, H., et al. (2000). Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine, 6(8), 916-919.
4. Behl, C. (2000). Apoptosis and Alzheimer's disease. Journal of Neural Transmission, 107(11), 1325-1344.
5. Bennett, S. P., Boyd, T., Norden, M., Padmanabhan, J., Neame, P., Wefes, I., et al. (2009). A novel technique for simultaneous bilateral brain infusions in a mouse model of neurodegenerative disease. Journal of Neuroscience Methods, 184(2), 320-326.
6. Bharathi, Shama Sundar, N. M., Rao, T. S. S., Ravid, R., & Rao, K. S. J. (2006). A new insight into Al-maltolate treated aged rabbit brain as Alzheimer's animal model. Brain Research Reviews, 52(2), 275-292.
7. Billings, L. M., Oddo, S., Green, K. N., McGaugh, J. L., & LaFerla, F. M. (2005). Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron, 45(5), 675-688.
8. Calissano, P., Matrone, C., & Amadoro, G. (2009). Apoptosis and in vitro Alzheimer disease neuronal models. Communicative and Integrative Biology, 2(2), 163-169.
9. Capsoni, S., & Cattaneo, A. (2006). On the molecular basis linking nerve growth factor (NGF) to Alzheimer's disease. Cell and Molecular Neurobiology, 26(4-6), 619-633.
10. Citron, M. (2002). Alzheimer's disease: treatments in discovery and development. Nature Neuroscience, 5(Suppl), 1055-1057.
11. DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J. C., Paul, S. M., & Holtzman, D. M. (2001). Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proceedings of National Academy of Sciences USA, 98(15), 8850-8855.
12. Dhenain, M., El Tannir El Tayara, N., Wu, T. D., Guegan, M., Volk, A., & Quintana, C., et al. (2009). Characterization of in vivo MRI detectable thalamic amyloid plaques from APP/PS1 mice. Neurobiology of Aging, 30(1), 41-53.
13. Dickson,D.W. (2004). Apoptoticmechanisms in Alzheimer neurofibrillary degeneration: Cause or effect? Journal of Clinical Investigation, 114(1), 23-27.
14. Dong, Y., Zhang, G., Zhang, B., Moir, R. D., Xia, W., Marcantonio, E. R., et al. (2009). The common inhalational anesthetic sevoflurane induces apoptosis and increases β-amyloid protein levels. Archives of Neurology, 66(5), 620-631.
15. Du, J., Sun, B., Chen, K., Zhang, L., Liu, S., Gu, Q., et al. (2009). Metabolites of cerebellar neurons and hippocampal neurons play opposite roles in pathogenesis of Alzheimer's disease. PLoSONE, 4(5), e5530.
16. Feng, Y., Wang, X. P., Yang, S. G., Wang, Y. J., Zhang, X., Du, X. T., et al. (2009). Resveratrol inh'ibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology, 30(6), 986-995.
17. Garcia-Sierra, F., Mondragon-Rodriguez, S., & Basurto-Islas, G. (2008). Truncation of tau protein and its pathological significance in Alzheimer's disease. Journal of Alzheimers Disease, 14(4), 401-409.
18. Garringer, H. J., Murrell, J., D'Adamio, L., Ghetti, B., & Vidal, R. (in press).Modeling familial British and Danish dementia. Brain Structure and Function.
19. Gaspar, R. C., Villarreal, S. A., Bowles, N., Hepler, R. W., Joyce, J. G., & Shughrue, P. J. (in press). Oligomers of beta-amyloid are sequestered into and seed plaques in the brains of an AD mouse model. Experimental Neurology.
20. Gerhard, G. S., Kauffman, E. J., Wang, X., Stewart, R., Moore, J. L., Kasales, et al. (2002). Life spans and senescent phenotypes in two strains of Zebrafish (Danio rerio). Experimental Gerontology, 37(8-9), 1055-1068.
21. Ghribi, O., DeWitt, D. A., Forbes, M. S., Arad, A., Herman, M. M., & Savory, J. (2001a). Cyclosporin A inhibits Al-induced cytochrome c release from mitochondria in aged rabbits. Journal of Alzheimers Disease, 3(4), 387-391.
22. Ghribi,O., DeWitt,D. A., Forbes, M. S.,Herman, M. M., &Savory, J. (2001). Coinvolvement of mitochondria and endoplasmic reticulum in regulation of apoptosis: changes in cytochrome c, Bcl-2 and Bax in the hippocampus of aluminum-treated rabbits. Brain Research, 903(1-2), 66-73.
23. Ghribi, O., Herman, M. M., DeWitt, D. A., Forbes, M. S., & Savory, J. (2001). Abeta(1-42) and aluminum induce stress in the endoplasmic reticulum in rabbit hippocampus, involving nuclear translocation of GADD 153 and NF-kappaB. Brain Research Molecular Brain Research, 96(1-2), 30-38.
24. Ghribi, O., Herman, M. M., Forbes, M. S., DeWitt, D. A., & Savory, J. (2001). GDNF protects against aluminum-induced apoptosis in rabbits by upregulating Bcl-2 and Bcl-XL and inhibiting mitochondrial Bax translocation. Neurobiology of Disease, 8(5), 764-773.
25. Ghribi, O., Herman, M. M., & Savory, J. (2002). The endoplasmic reticulum is the main site for caspase-3 activation following aluminum-induced neurotoxicity in rabbit hippocampus. Neuroscience Letters, 324(3), 217-221.
26. Gotz, J., Gladbach, A., Pennanen, L., van Eersel, J., Schild, A., David, D., et al. (in press). Animal models reveal role for tau phosphorylation in human disease. Biochimica Biophysica Acta.
27. Hook, V. Y., Kindy, M., & Hook, G. (2008). Inhibitors of cathepsin B improve memory and reduce beta-amyloid in transgenic Alzheimer disease mice expressing the wild-type, but not the Swedishmutant, beta-secretase site of the amyloid precursor protein. Journal of Biological Chemistry, 283(12), 7745-7753.
28. Hutton, M., Lendon, C. L., Rizzu, P., Baker, M., Froelich, S., Houlden, H., et al. (1998). Association of missense and 5′-splicesite mutations in tau with the inherited dementia FTDP-17. Nature, 393(6686), 702-705.
29. Jack, C. R., Jr., Garwood, M., Wengenack, T. M., Borowski, B., Curran, G. L., Lin, J., et al. (2004). In vivo visualization of Alzheimer's amyloid plaques by magnetic resonance imaging in transgenic mice without a contrast agent. Magnetic Resonance in Medicine, 52(6), 1263-1271.
30. Jack, C. R., Jr., Marjanska,M.,Wengenack, T. M., Reyes, D. A., Curran, G. L., Lin, J., et al. (2007). Magnetic resonance imaging of Alzheimer's pathology in the brains of living transgenic mice: a new tool in Alzheimer's disease research. Neuroscientist, 13(1), 38-48.
31. Jack, C. R., Jr., Wengenack, T. M., Reyes, D. A., Garwood, M., Curran, G. L., Borowski, B. J., et al. (2005). In vivo magnetic resonance microimaging of individual amyloid plaques in Alzheimer's transgenic mice. Journal of Neuroscience, 25(43), 10041-10048.
32. Jantzen, P. T., Connor, K. E., DiCarlo, G., Wenk, G. L., Wallace, J. L., Rojiani, A. M., et al. (2002). Microglial activation and betaamyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. Journal of Neuroscience, 22(6), 2246-2254.
33. Jeong, J. Y., Kwon, H. B., Ahn, J. C., Kang, D., Kwon, S. H., Park, J. A., et al. (2008). Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Research Bulletin, 75(5), 619-628.
34. Lim, G. P., Chu, T., Yang, F. S., Beech, W., Frautschy, S. A., & Cole, G. M. (2001). The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Journal of Neuroscience, 21(21), 8370-8377.
35. Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W., Teter, B., et al. (2000). Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. Journal of Neuroscience, 20(15), 5709-5714.
36. Lim, G. P., Yang, F., Chu, T., Gahtan, E., Ubeda, O., Beech,W., et al. (2001). Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiology of Aging, 22(6), 983-991.
37. Price, K. A., Caragounis, A., Paterson, B. M., Filiz, G., Volitakis, I., Masters, C. L., et al. (2009). Sustained Activation of glial cell epidermal growth factor receptor by bis(thiosemicarbazonato) metal complexes is associated with inhibition of protein tyrosine phosphatase activity. Journal of Medicinal Chemistry, 52(21), 6606-6620.
38. Mattson, M. P., & Magnus, T. (2006). Ageing and neuronal vulnerability. Nature Reviews Neuroscience, 7(4), 278-294.
39. Maxwell, M. M. (2009). RNAi applications in therapy development for neurodegenerative disease. Current Pharmaceutical Design, 15(34), 3977-3991.
40. Manzano, S., Gonzalez, J., Marcos, A., Payno, M., Villanueva, C., & Matias-Guiu, J. (2009). Experimental models in Alzheimer's disease. Neurologia, 24(4), 255-262.
41. Meadowcroft, M. D., Connor, J. R., Smith, M. B., & Yang, Q. X. (2009). Magnetic resonance imaging and histological analysis of beta-amyloid plaques in both human Alzheimer's disease and APP/PS1 transgenic mice. Journal of Magnetic Resonance and Imaging, 29(5), 997-1007.
42. Miltiadous, P., Stamatakis, A., & Stylianopoulou, F. (in press). Neuroprotective effects of IGF-I following kainic acid-induced hippocampal degeneration in the rat. Cell and Molecular Neurobiology.
43. Movsesyan, N., Ghochikyan, A., Mkrtichyan, M., Petrushina, I., Davtyan, H., Olkhanud, P. B., et al. (2008). Reducing ADlike pathology in 3xTg-AD mouse model by DNA epitope vaccine-A novel immunotherapeutic strategy. PLoS ONE, 3(5), e2124.
44. Murphy, M. P., & Levine, H. (2010). Alzheimer's disease and the amyloid-beta peptide. Journal of Alzheimers Disease, 19(1), 311-323.
45. Obulesu, M., Rao, D. M., & Shama Sundar, N. M. (2009). Studies on genomic DNA stability in aluminium-maltolate treated aged New Zealand rabbit: Relevance to the Alzheimer's animal model. Journal of Clinical Medicine and Research, 1(4), 212-218.
46. Oddo, S., Billings, L., Kesslak, J. P., Cribbs, D. H., & LaFerla, F. M. (2004). Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 43(3), 321-332.
47. Oddo, S.,Caccamo,A., Shepherd, J. D.,Murphy,M. P.,Golde,T.E., Kayed, R., et al. (2003). Triple-transgenic model of Alzheimer's disease with plaques and tangles: Intracellular Abeta and synaptic dysfunction. Neuron, 39(3), 409-421.
48. Oddo, S., Vasilevko, V., Caccamo, A., Kitazawa,M., Cribbs, D. H., & LaFerla, F. M. (2006). Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. Journal of Biological Chemistry, 281(51), 39413-39423.
49. Paquet, D., Bhat, R., Sydow, A., Mandelkow, E. M., Berg, S., Hellberg, S., et al. (2009). A zebrafish model of tauopathy allows in vivo imaging of neuronal cell death and drug evaluation. Journal of Clinical Investigation, 119(5), 1382-1395.
50. Peng, Y., Xing, C., Xu, S., Lemere, C. A., Chen, G., Liu, B., et al. (2009). l-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloidbeta peptide in rats. European Journal of Pharmacology, 621(1-3), 38-45.
51. Polydoro, M., Acker, C. M., Duff, K., Castillo, P. E., & Davies, P. (2009). Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. Journal of Neuroscience, 29(34), 10741-10749.
52. Ramalho, R. M., Viana, R. J., Castro, R. E., Steer, C. J., Low, W. C., & Rodriguez, C. M. (2008). Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Molecular medicine, 14(5-6), 309-317.
53. Rao, K. S. J., Anitha, S., & Latha, K. S. (2000). Aluminium induced neurodegeneration in hippocampus of aged rabbits mimics AD. Alzheimer's Reports, 3, 83-88.
54. Rohn, T. T., Vyas, V., Hernandez-estrada, T., Nichol, K. E., Christie, L. A., & Head, E. (2008). Lack of pathology in a triple transgenic mouse model of Alzheimer's disease after overexpression of the antiapoptotic protein bcl-2. Journal of Neuroscience, 28(12), 3051-3059.
55. Roberts, R. C. (1961). The lifetime growth and reproduction of selected strains of mice. Heredity, 16, 369-381.
56. Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., et al. (2000). Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen and skeletal muscle dystrophy. Journal of Neuroscience, 20(7), 2589-2601.
57. Savory, J., Jagannatha, K. S. Rao., Yue, H., Philip, R., Ledata, et al. (1999). Age-related hippocampal changes in Bcl3-2: Bax Ratio, Oxidative Stress, Redox-Active iron and apoptosis associated with Al induced neurodegeneration: Increased susceptibility with aging. Neurotoxicology, 20(5), 805-818.
58. Schenk, D., Barbour, R., Dunn,W., Gordon, G., Grajeda, H., Guido, T., et al. (1999). Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 400, 173-177.
59. Shimohama, S. (2000). Apoptosis in Alzheimer's disease-An update. Apoptosis, 5(1), 9-16.
60. Shi, Q., & Gibson, G. E. (2007). Oxidative stress and transcriptional regulation in Alzheimer disease. Alzheimer Disease and Associated Disorders, 21(4), 276-291.
61. Small, G. W., Rabins, P. V., Barry, P. P. Buckholtz, N. S., DeKosky, S. T., Ferris, S. H., et al. (1997). Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. The Journal of the American Medical Association, 278(16), 1363-1371.
62. Squitti, R., & Salustri, C. (2009). Agents complexing copper as a therapeutic strategy for the treatment of Alzheimer's disease. Current Alzheimer's Research, 6(6), 476-487.
63. Sugama, S., Takenouchi, T., Cho, B. P., Joh, T. H., Hashimoto, M., & Kitani, H. (2009). Possible roles of microglial cells for neurotoxicity in clinical neurodegenerative diseases and experimental animal models. Inflammation and Allergy Drug Targets, 8, 277-284.
64. Terrence Town. (2009). Alternative Aβimmunotherapy approaches for Alzheimer's disease.CNS and Neurological Desorders Drug Targets, 8(4), 144-1127
65. Tomasiewicz, H. G., Flaherty, D. B., Soria, J. P., & Wood, J. G. (2002). Transgenic zebrafish model of neurodegeneration. Journal of Neuroscience Research, 70(6), 734-745.
66. Trinchese, F., Fa, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S. D., et al. (2008). Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. Journal of Clinical Investigation, 118(8), 2796-2807.
67. Vanhoutte, G., Dewachter, I., Borghgraef, P., Van Leuven, F., & Van Der Linden, A. (2005). Noninvasive in vivo MRI detection of neuritic plaques associated with iron in APP[V717I] transgenic mice, a model for Alzheimer's disease. Magnetic Resonance in Medicine, 53(3), 607-613.
68. van Groen, T., Kiliaan, A. J., & Kadish, I. (2006). Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. Neurobiology of Disease, 23(3), 653-662.
69. Velliquette, R. A., O'Connor, T., & Vassar, R. (2005). Energy inhibition elevates betasecretase levels and activity and is potentially amyloidogenic in APP transgenic mice: Possible early events in Alzheimer's disease pathogenesis. Journal of Neuroscience, 25(47), 10874-10883.
70. Wengenack, T. M.,Whelan, S., Curran,G. L.,Duff, K. E., & Poduslo, J. F. (2000). Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience, 101(4), 939-944.
71. Wright, J. W., & Harding, J. W. (in press). The brain RAS and Alzheimer's disease. Experimental Neurology.
72. Zon, L. I., & Peterson, R. T.,(2005). In vivo drug discovery in the zebrafish. Nature Reviews Drug Discovery, 4(1), 35-44.